GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Chordia Therapeutics Inc (TSE:190A) » Definitions » Additional Paid-In Capital

Chordia Therapeutics (TSE:190A) Additional Paid-In Capital : 円9,065.87 Mil(As of Feb. 2025)


View and export this data going back to 2024. Start your Free Trial

What is Chordia Therapeutics Additional Paid-In Capital?


Chordia Therapeutics's quarterly additional paid-in capital increased from May. 2024 (円8,279.60 Mil) to Aug. 2024 (円9,034.87 Mil) and increased from Aug. 2024 (円9,034.87 Mil) to Feb. 2025 (円9,065.87 Mil).

Chordia Therapeutics's annual additional paid-in capital increased from Aug. 2022 (円2,872.66 Mil) to Aug. 2023 (円8,279.60 Mil) and increased from Aug. 2023 (円8,279.60 Mil) to Aug. 2024 (円9,034.87 Mil).


Chordia Therapeutics Additional Paid-In Capital Historical Data

The historical data trend for Chordia Therapeutics's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chordia Therapeutics Additional Paid-In Capital Chart

Chordia Therapeutics Annual Data
Trend Aug21 Aug22 Aug23 Aug24
Additional Paid-In Capital
870.08 2,872.66 8,279.60 9,034.87

Chordia Therapeutics Quarterly Data
Aug21 Aug22 May23 Aug23 May24 Aug24 Feb25
Additional Paid-In Capital Get a 7-Day Free Trial 8,279.60 8,279.60 8,279.60 9,034.87 9,065.87

Chordia Therapeutics Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)

Chordia Therapeutics Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Chordia Therapeutics's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.


Chordia Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
2-26-1 Muraoka-Higashi, Kanagawa, Fujisawa, JPN, 251-0012
Chordia Therapeutics Inc is a bio-venture company specializing in cancer research and development. Its mission is to deliver first-in-class cancer drugs to patients. It is a clinical-stage biotech company engaged in researching and developing novel therapies for cancers with high unmet medical needs.

Chordia Therapeutics Headlines

No Headlines